knowledge -WSS

knowledge

author：fashion 2025-09-06 03:15:12 - browse：7781

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Novo Nordisk to expand supply of Wegovy for U.S. patients

leisure time

WSS

How to fix the rural physician shortage in the U.S.

FDA does about

Congress gives doctors Medicare pay bump

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

What we need to know about Arena Bioworks

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

hotspot

knowledge

hotspot

New air purifier tech could be key to improving indoor air quality

FDA does about

Wildfire smoke exposes gaps in outdoor worker protections

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Peter Hotez and the public health issue of online harassment

Change Healthcare cyberattack outage could last weeks

Wildfire smoke exposes gaps in outdoor worker protections

Covid misinformation case heads to Supreme Court

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

focus

An inside look at PIPEs, biotech's buzzy new financing tool

Kenai launches with $82 million for Parkinson’s stem cell therapy

Biotech companies concerned about China biosecurity crackdown

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Covid misinformation case heads to Supreme Court

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

leisure time

leisure time

focus

entertainment